Your browser doesn't support javascript.
loading
Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer.
Weitzel, Jeffrey N; Neuhausen, Susan L; Adamson, Aaron; Tao, Shu; Ricker, Charité; Maoz, Asaf; Rosenblatt, Margalit; Nehoray, Bita; Sand, Sharon; Steele, Linda; Unzeitig, Gary; Feldman, Nancy; Blanco, Amie M; Hu, Donglei; Huntsman, Scott; Castillo, Danielle; Haiman, Christopher; Slavin, Thomas; Ziv, Elad.
Afiliación
  • Weitzel JN; Division of Clinical Cancer Genomics, City of Hope, Duarte, California.
  • Neuhausen SL; Clinical Cancer Genomics Community Research Network, Los Angeles, California.
  • Adamson A; Division of Biomarkers of Early Detection and Prevention, City of Hope, Duarte, California.
  • Tao S; Division of Biomarkers of Early Detection and Prevention, City of Hope, Duarte, California.
  • Ricker C; Integrative Genomics Core, City of Hope, Duarte, California.
  • Maoz A; Clinical Cancer Genomics Community Research Network, Los Angeles, California.
  • Rosenblatt M; University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California.
  • Nehoray B; University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California.
  • Sand S; University of California at San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California.
  • Steele L; Division of Clinical Cancer Genomics, City of Hope, Duarte, California.
  • Unzeitig G; Clinical Cancer Genomics Community Research Network, Los Angeles, California.
  • Feldman N; Division of Clinical Cancer Genomics, City of Hope, Duarte, California.
  • Blanco AM; Clinical Cancer Genomics Community Research Network, Los Angeles, California.
  • Hu D; Division of Biomarkers of Early Detection and Prevention, City of Hope, Duarte, California.
  • Huntsman S; Clinical Cancer Genomics Community Research Network, Los Angeles, California.
  • Castillo D; Gary Unzeitig MD Office, Laredo, Texas.
  • Haiman C; Clinical Cancer Genomics Community Research Network, Los Angeles, California.
  • Slavin T; University of California at San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California.
  • Ziv E; Division of General Internal Medicine, Department of Medicine, University of California at San Francisco, San Francisco, California.
Cancer ; 125(16): 2829-2836, 2019 08 15.
Article en En | MEDLINE | ID: mdl-31206626
BACKGROUND: Breast cancer (BC) is the most common cancer and related cause of mortality among Hispanics, yet susceptibility has been understudied. BRCA1 and BRCA2 (BRCA) mutations explain less than one-half of hereditary BC, and the proportion associated with other BC susceptibility genes is unknown. METHODS: Germline DNA from 1054 BRCA-mutation-negative Hispanic women with hereditary BC (BC diagnosed at age <51 years, bilateral BC, breast and ovarian cancer, or BC diagnosed at ages 51-70 years with ≥2 first-degree or second-degree relatives who had BC diagnosed at age <70 years), 312 local controls, and 887 multiethnic cohort controls was sequenced and analyzed for 12 known and suspected, high-penetrance and moderate-penetrance cancer susceptibility genes (ataxia telangiectasia mutated [ATM], breast cancer 1 interacting protein C-terminal helicase 1 [BRIP1], cadherin 1 [CDH1], checkpoint kinase 2 [CHEK2], nibrin [NBN], neurofibromatosis type 1 [NF1], partner and localizer of BRCA2 [PALB2], phosphatase and tensin homolog [PTEN], RAD51 paralog 3 [RAD51C], RAD51D, serine/threonine kinase 11 [STK11], and TP53). RESULTS: Forty-nine (4.6%) pathogenic or likely pathogenic variants (PVs) in 47 of 1054 participants (4.5%), including 21 truncating frameshift, 20 missense, 5 nonsense, and 4 splice variants, were identified in CHEK2 (n = 20), PALB2 (n = 18), ATM (n = 5), TP53 (n = 3), BRIP1 (n = 2), and CDH1 and NF1 (both n = 1) and none were identified in NBN, PTEN, STK11, RAD51C, or RAD51D. Nine participants carried the PALB2 c.2167_2168del PV (0.85%), and 14 carried the CHEK2 c.707T>C PV (1.32%). CONCLUSIONS: Of 1054 BRCA-negative, high-risk Hispanic women, 4.5% carried a PV in a cancer susceptibility gene, increasing understanding of hereditary BC in this population. Recurrent PVs in PALB2 and CHEK2 represented 47% (23 of 49) of the total, suggesting a founder effect. Accurate classification of variants was enabled by carefully controlling for ancestry and the increased identification of at-risk Hispanics for screening and prevention.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Quinasa de Punto de Control 2 / Proteína del Grupo de Complementación N de la Anemia de Fanconi Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Aged / Female / Humans / Middle aged Idioma: En Revista: Cancer Año: 2019 Tipo del documento: Article

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Quinasa de Punto de Control 2 / Proteína del Grupo de Complementación N de la Anemia de Fanconi Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Aged / Female / Humans / Middle aged Idioma: En Revista: Cancer Año: 2019 Tipo del documento: Article